Summit has entered into an exclusive license and collaboration agreement with Sarepta for its utrophin modulation pipeline, including its lead DMD programme ezutromid, in Europe. We believe this is highly value enhancing and a good strategic fit. The deal is substantial and Summit retains commercialisation rights in the US market where it will market the drug on its own, offering significant upside potential. In this note we provide a detailed overview of the deal and update our forecasts. We look forward to the partnership progressing and bringing treatments to DMD patients.
